ATE292966T1 - Methode zur synthetisierung von leflunomid - Google Patents

Methode zur synthetisierung von leflunomid

Info

Publication number
ATE292966T1
ATE292966T1 AT01907127T AT01907127T ATE292966T1 AT E292966 T1 ATE292966 T1 AT E292966T1 AT 01907127 T AT01907127 T AT 01907127T AT 01907127 T AT01907127 T AT 01907127T AT E292966 T1 ATE292966 T1 AT E292966T1
Authority
AT
Austria
Prior art keywords
leflunomide
trifluoromethylphenyl
isoxazole
carboxamide
methyl
Prior art date
Application number
AT01907127T
Other languages
English (en)
Inventor
Ilya Avrutov
Neomi Gershon
Anita Liberman
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE292966T1 publication Critical patent/ATE292966T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01907127T 2000-02-15 2001-02-08 Methode zur synthetisierung von leflunomid ATE292966T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18263500P 2000-02-15 2000-02-15
PCT/US2001/004095 WO2001060363A1 (en) 2000-02-15 2001-02-08 A method for synthesizing leflunomide

Publications (1)

Publication Number Publication Date
ATE292966T1 true ATE292966T1 (de) 2005-04-15

Family

ID=22669359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907127T ATE292966T1 (de) 2000-02-15 2001-02-08 Methode zur synthetisierung von leflunomid

Country Status (18)

Country Link
US (2) US6723855B2 (de)
EP (1) EP1257270B1 (de)
JP (1) JP2004500380A (de)
KR (1) KR20020072312A (de)
AT (1) ATE292966T1 (de)
AU (1) AU2001234943A1 (de)
CA (1) CA2400290A1 (de)
CZ (1) CZ20023024A3 (de)
DE (1) DE60110043T2 (de)
ES (1) ES2237553T3 (de)
HR (1) HRP20020671A2 (de)
HU (1) HUP0301865A3 (de)
IL (1) IL151196A0 (de)
PL (1) PL366088A1 (de)
SK (1) SK12992002A3 (de)
WO (1) WO2001060363A1 (de)
YU (1) YU61602A (de)
ZA (1) ZA200206494B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2003042193A1 (en) * 2001-11-09 2003-05-22 Geneva Pharmaceuticals, Inc. Process for preparing 5-methylisoxazole-4-carboxylic-(4'-trifluoromethyl)-anilide
BRPI0410704A (pt) * 2003-05-27 2006-06-13 Robert Per Hogerkvist uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete
EP1694308A1 (de) * 2003-10-30 2006-08-30 Lupin Ltd. Stabile formulierungen von ace-hemmern und herstellungsverfahren dafür
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
WO2007086076A2 (en) * 2006-01-24 2007-08-02 Unichem Laboratories Limited An improved process for preparation of leflunomide
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
CR20170078A (es) 2009-09-18 2017-05-22 Sanofi Sa Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada
CN102002009B (zh) * 2010-10-18 2012-11-07 齐鲁制药有限公司 一种5-甲基异恶唑-4-甲酰氯的制备方法
JP6797839B2 (ja) * 2015-06-17 2020-12-09 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ テリフルノミドの新規製造方法
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
GB8619432D0 (en) 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
DK0527736T3 (da) * 1990-05-18 1997-10-20 Hoechst Ag Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
DE59407413D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it

Also Published As

Publication number Publication date
ZA200206494B (en) 2003-08-20
HUP0301865A3 (en) 2005-12-28
AU2001234943A1 (en) 2001-08-27
ES2237553T3 (es) 2005-08-01
CA2400290A1 (en) 2001-08-23
YU61602A (sh) 2006-01-16
EP1257270A4 (de) 2003-05-07
DE60110043T2 (de) 2006-03-02
US20040127532A1 (en) 2004-07-01
US6723855B2 (en) 2004-04-20
PL366088A1 (en) 2005-01-24
KR20020072312A (ko) 2002-09-14
HUP0301865A2 (hu) 2003-09-29
HRP20020671A2 (en) 2004-12-31
CZ20023024A3 (cs) 2003-05-14
IL151196A0 (en) 2003-04-10
US20020022646A1 (en) 2002-02-21
DE60110043D1 (de) 2005-05-19
SK12992002A3 (sk) 2003-05-02
EP1257270A1 (de) 2002-11-20
JP2004500380A (ja) 2004-01-08
WO2001060363A1 (en) 2001-08-23
EP1257270B1 (de) 2005-04-13

Similar Documents

Publication Publication Date Title
ATE292966T1 (de) Methode zur synthetisierung von leflunomid
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
HUP0301802A2 (hu) Eljárás carvedilol elżállítására, kristályos carvedilol, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
TW200500083A (en) Formulation of human antibodies for treating tnf-α associated disorders
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
IS6491A (is) Pteridínefnasambönd til meðhöndlunar á sóríasis
EA200600588A1 (ru) Соединения, содержащие галоидалкил, как ингибиторы цистеиновых протеаз
NO20061791L (no) Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin
HUP0204010A2 (hu) Új szertralin-hidroklorid polimorfok, eljárás az előállításukra, az új polimorfokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0302874A2 (hu) Eljárás risperidon előállítására
SG149045A1 (en) Novel fused pyrrolocarbazoles
MY149041A (en) Novel fused pyrrolocarbazoles
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
HUP0204069A2 (hu) Új eljárás leflunomid előállítására és a leflunomid új kristályformája és ezt tartalmazó gyógyszerkészítmény
SE0200844D0 (sv) Chemical compounds
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
DE602005027228D1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
ATE111455T1 (de) 3-substituierte 1,2,3,4-oxatriazol-5- iminderivate, verfahren zur herstellung sowie diese enthaltende arzneimittel.
ES2147365T3 (es) Un procedimiento para la preparacion del factor ix a partir de muestras biologicas.
DE602004031129D1 (de) Verfahren zur herstellung von quetiapin
DE60213450D1 (de) Chinolinderivate, herstellungsprozess und verwendung zur behandlung von krankheiten, bei den s-cd23 involviert ist

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties